ZOLYMBUS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZOLYMBUS (ZOLYMBUS).
ZOLYMBUS (ibrutinib) is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of B-cell receptor signaling and downstream pathways critical for B-cell proliferation, migration, and survival.
| Metabolism | Primarily metabolized by cytochrome P450 3A4 (CYP3A4). Minor metabolism via CYP2D6. |
| Excretion | Primarily hepatic metabolism with negligible renal excretion (<1% unchanged). Biliary/fecal elimination accounts for approximately 90% of the administered dose, with the remainder excreted in urine as metabolites. |
| Half-life | Terminal elimination half-life is approximately 26 hours (range 22–30 hours), supporting once-daily dosing for sustained therapeutic effect. |
| Protein binding | 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg (range 0.4–0.6 L/kg), indicating moderate tissue distribution. |
| Bioavailability | Oral bioavailability is 30% (range 25–35%). |
| Onset of Action | Intravenous: Onset within 5–10 minutes. Oral: Onset within 1–2 hours. |
| Duration of Action | Duration of action is 24 hours for blood pressure reduction when given intravenously; oral dosing provides 24-hour coverage with sustained trough levels. |
| Molecular Weight | 348.42 |
2 mg orally once daily.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min. |
| Liver impairment | Child-Pugh A: 2 mg once daily; Child-Pugh B or C: 1 mg once daily. |
| Pediatric use | 0.04 mg/kg orally once daily; maximum 2 mg/day. |
| Geriatric use | No specific dose adjustment; monitor for increased sensitivity and adverse effects. |
| 1st trimester | Zolymbus is contraindicated in the first trimester due to teratogenicity. Animal studies have shown fetal malformations; human data are limited but suggest risk. |
| 2nd trimester | Use in the second trimester only if maternal benefit outweighs fetal risk, with close monitoring for oligohydramnios and fetal growth restriction. |
| 3rd trimester | Avoid in the third trimester due to risk of premature ductus arteriosus closure and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for ZOLYMBUS (ZOLYMBUS).
| Placental transfer | Extensive placental transfer documented; cord blood concentrations are approximately 70-80% of maternal serum levels. |
| Breastfeeding | Zolymbus is excreted into human milk in small amounts. Due to potential for adverse effects in the infant (e.g., renal impairment, gastrointestinal disturbances), breastfeeding is not recommended during therapy. If essential, pump and discard milk during treatment and for 5 half-lives after last dose. |
■ FDA Black Box Warning
Hemorrhage: Fatal bleeding events have occurred in patients treated with ZOLYMBUS. Grade 3 or higher bleeding events (intracranial, gastrointestinal, hematuria) have been reported. Monitor for signs and symptoms of bleeding. Consider the benefit-risk of withholding ZOLYMBUS for 3-7 days pre- and post-surgery.
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to Zolymbus or any excipientSevere hepatic impairment (Child-Pugh C)Concomitant use with strong CYP3A4 inducers
| Precautions | Hemorrhage: Monitor for bleeding; consider anticoagulant use cautiously., Infections: Fatal and non-fatal infections have occurred; monitor for signs and treat promptly., Cytopenias: Neutropenia, thrombocytopenia, and anemia can occur; monitor blood counts regularly., Cardiac arrhythmias: Atrial fibrillation and other arrhythmias have been reported; monitor and manage appropriately., Hypertension: Monitor blood pressure and manage as needed., Second primary malignancies: Including non-melanoma skin cancer; advise sun protection., Tumor lysis syndrome: Risk in patients with high tumor burden; ensure adequate hydration and prophylaxis., Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of fetal malformations including neural tube defects, cardiovascular anomalies, and oral clefts. Second and third trimesters: Increased risk of oligohydramnios and fetal renal dysfunction. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor pregnancy status before and during therapy. Inadvertent exposure: immediate ultrasound for fetal anomalies, serial fetal growth scans, amniotic fluid volume assessment, and renal function evaluation. |
| Fertility Effects | May impair fertility in females due to ovarian dysfunction and hormonal alterations. In males, possible decreased spermatogenesis. Reversible upon discontinuation in most cases. |
| Food/Dietary |
| Grapefruit and grapefruit juice may increase ethinyl estradiol levels; avoid concurrent consumption. St. John's wort may reduce contraceptive efficacy; avoid combination. No other significant food interactions. No restrictions on caffeine, alcohol (in moderation; avoid excessive use), or tyramine-containing foods. |
| Clinical Pearls | ZOLYMBUS (ethinyl estradiol/norethindrone acetate) is a combination oral contraceptive that effectively treats moderate acne vulgaris in females ≥15 years. Obtain a thorough history for contraindications including smoking ≥35 years, hypertension, migraine with aura, thromboembolic disorders, breast cancer, liver disease, or pregnancy. Monitor for symptoms of VTE, MI, stroke, and hepatotoxicity. Counsel on irregular bleeding, especially in first cycles; if persistent, evaluate for pregnancy or other causes. Consider alternative contraception if patient is on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) or rifampin. Drug may be less effective in perimenopausal women due to age-related fertility decline. |
| Patient Advice | Take one tablet daily at the same time each day, with or without food. · If you miss a dose, follow the instructions in the package insert; use backup contraception as directed. · Do not smoke while taking this medication, especially if you are over 35 years old, due to increased risk of serious cardiovascular events. · Contact your healthcare provider immediately if you experience leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes, or jaundice. · This medication does not protect against HIV or other sexually transmitted infections. · Tell your doctor about all medications you take, including over-the-counter drugs and supplements. · If you become pregnant or plan to breastfeed, consult your doctor; discontinue use if pregnancy occurs. · Regular gynecologic exams and blood pressure monitoring are recommended. |